Magnite's high P/S ratio is surprising considering its future revenue forecasts align with the industry. The high share price may not last unless it outperforms the industry soon. Investors could face disappointment if the P/S aligns with the growth outlook.
The company's balance sheet is considered strained due to its EBIT loss and the liabilities on its balance sheet relative to cash. It is deemed unwise for the company to have any debt. The stock is considered really risky.
Multiple insiders selling shares over the past year could be a red flag. However, insiders owning a fair amount of shares suggests alignment with shareholders. Lack of insider purchases in the past year is not encouraging.
Magnite's high P/S ratio, compared to typical industry growth forecasts, could risk current and prospective investors. Shareholders could face letdown if the P/S ratio aligns with its growth outlook, meaning potential investors could pay an unwarranted premium for the stock.
Magnite股票討論區
In reaction to earnings/guidance:
• $The Trade Desk(TTD.US)$+17%, $Workiva(WK.US)$ +15.3%, $Arlo Technologies(ARLO.US)$ +12%, $Array Technologies(ARRY.US)$ +10.3%, $Everbridge(EVBG.US)$ +9.7%, $Catalyst Pharmaceuticals(CPRX.US)$ +9.4%, $奧洛茲美醫療(HALO.US)$ +8.7%, $Velo3D(VLD.US)$ +7.6%, $CyberArk(CYBR.US)$ + 6.2%, $美國血液技術(HAE.US)$ +5.8%, $Jackson Financial(JXN.US)$ +5.7% (also increases dividend), $Axon Enterprise(AXON.US)$ +4.8%,...
暫無評論